Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN

Open source

DOI: 10.1200/jco.23.00562
Published: 2023 Aug 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.23.00562,
  title = {Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.},
  author = {Wang ML and Jurczak W and Zinzani PL and Eyre TA and Cheah CY and Ujjani CS and Koh Y and Izutsu K and Gerson JN and Flinn I and Tessoulin B and Alencar AJ and Ma S and Lewis D and Lech-Maranda E and Rhodes J and Patel K and Maddocks K and Lamanna N and Wang Y and Tam CS and Munir T and Nagai H and Hernandez-Ilizaliturri F and Kumar A and Fenske TS and Seymour JF and Zelenetz AD and Nair B and Tsai DE and Balbas M and Walgren RA and Abada P and Wang C and Zhao J and Mato AR and Shah NN},
  year = {2023},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.23.00562},
  url = {https://doi.org/10.1200/jco.23.00562}
}

RIS

TY  - JOUR
TI  - Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
AU  - Wang ML
AU  - Jurczak W
AU  - Zinzani PL
AU  - Eyre TA
AU  - Cheah CY
AU  - Ujjani CS
AU  - Koh Y
AU  - Izutsu K
AU  - Gerson JN
AU  - Flinn I
AU  - Tessoulin B
AU  - Alencar AJ
AU  - Ma S
AU  - Lewis D
AU  - Lech-Maranda E
AU  - Rhodes J
AU  - Patel K
AU  - Maddocks K
AU  - Lamanna N
AU  - Wang Y
AU  - Tam CS
AU  - Munir T
AU  - Nagai H
AU  - Hernandez-Ilizaliturri F
AU  - Kumar A
AU  - Fenske TS
AU  - Seymour JF
AU  - Zelenetz AD
AU  - Nair B
AU  - Tsai DE
AU  - Balbas M
AU  - Walgren RA
AU  - Abada P
AU  - Wang C
AU  - Zhao J
AU  - Mato AR
AU  - Shah NN
PY  - 2023
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.23.00562
UR  - https://doi.org/10.1200/jco.23.00562
ER  -

APA

ML, W., W, J., PL, Z., TA, E., CY, C., CS, U., Y, K., K, I., JN, G., I, F., B, T., AJ, A., S, M., D, L., E, L., J, R., K, P., K, M., N, L., Y, W., CS, T., T, M., H, N., F, H., A, K., TS, F., JF, S., AD, Z., B, N., DE, T., M, B., RA, W., P, A., C, W., J, Z., AR, M., & NN, S. (2023). Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.23.00562

Source records

pubmed · retrieved 2026-09-27T16:46:08.333Z